Zhejiang Wild Wind Pharmaceutical

Zhejiang Wild Wind Pharmaceutical is a prominent Chinese pharmaceutical enterprise focused on the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and high-end intermediates. The company holds a significant global market share in the production of anti-Parkinson's disease medications, most notably Methyldopa, Levodopa, and Carbidopa. Beyond neurology, Wild Wind has expanded its portfolio into advanced antifungal agents such as Caspofungin and Micafungin, as well as cardiovascular therapies. The firm operates state-of-the-art manufacturing bases that comply with international GMP standards, including approvals from the US FDA and EU authorities. As a key subsidiary of the Wild Wind Group, the company leverages integrated chemical synthesis and fermentation technologies to supply the global generic pharmaceutical industry.